RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07349-1 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von YanSong Lin und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. liny…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyrotropin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Suzhou Zelgen Biopharmaceuticals Co., Ltd..
Abstract (Originalsprache)
PURPOSE: To evaluate the efficacy of a novel recombinant human thyroid-stimulating hormone (ZGrhTSH) as an alternative to thyroid hormone withdrawal (THW) in dynamic assessment of DTC patients. METHODS: This phase 3, open-label, multicenter trial, conducted across 27 sites in China, employed a self-controlled design to enroll patients. Eligible patients had previously undergone total or near-total thyroidectomy, with or without RAI therapy. During both the ZGrhTSH-stimulated phase and the THW phase, Dx-WBS and serum Tg measurements were performed on all participants. The study focused on the concordance of Dx-WBS results, stimulated Tg levels, and their combination in patients across the two phases. Additionally, the safety and immunogenicity profiles of ZGrhTSH were assessed as well. RESULTS: In the assessment of radioiodine uptake and stimulated Tg levels, ZGrhTSH demonstrated efficacy comparable to that of THW. The concordance rate for scans between the two phases was 88.2% (95% CI: 83.7-92.7%). When setting stimulated Tg levels with a cutoff of 1 ng/mL, the concordance rate was 90.4% (95% CI: 86.1-94.6%), and the concordance of scans combined with stimulated Tg was 93.6% (95% CI: 90.1-97.1%). Adverse events associated with ZGrhTSH were reported in 22 patients (10.9%), all of which were mild and transient, graded as 1 or 2. CONCLUSION: ZGrhTSH showed non-inferior performance in detecting radioiodine uptake and serum Tg, and could be an effective and safe alternative for the dynamic evaluation of DTC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04971473. Registered July 7, 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China. linyansong1968@163.com.
- China-Japan Union Hospital of Jilin University, Changchun, China.
- The First Affiliated Hospital of Guilin Medical University, Guilin, China.
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- Henan Provincial People's Hospital, Zhengzhou, China.
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: YanSong Lin
Förderung
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Zitieren
APA
Lin, Y., Wen, Q., Fu, W., Yang, H., Gao, Y., Li, Z., Huang, J., Gao, Z., Wu, J., Lv, Z., Lu, K., Chen, Y., Yang, A., OuYang, W., Zhang, S., Zhou, H., Deng, Z., Chen, Z., Ding, Y., …, & Cheng, Y. (2025). RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07349-1
Vancouver
Lin Y, Wen Q, Fu W, Yang H, Gao Y, Li Z, et al. RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07349-1
BibTeX
@article{Lin2025,
author = {Lin, YanSong and Wen, Qiang and Fu, Wei and Yang, Hui and Gao, YongJu and Li, ZhiYong and Huang, JinXiong and Gao, ZaiRong and Wu, Jing and Lv, ZhongWei and Lu, KeYi and Chen, Yue and Yang, AiMin and OuYang, Wei and Zhang, ShuiXing and Zhou, HaiZhong and Deng, ZhiYong and Chen, ZhiJun and Ding, Yong and Yuan, Chao and Li, LinFa and Lin, ChengHe and Sang, ShiBiao and Cheng, ZhiFeng and Cheng, YiZhuang},
title = {RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07349-1}
}
EUVIMED